Yale Comprehensive Cancer Center Support Grant

耶鲁大学综合癌症中心支持补助金

• 批准号: 8917569
• 负责人: Thomas James Lynch
• 金额: $ 33.3万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-07-01 至 2018-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8917569
• 关键词: Aftercare; Basic Science; Biometry; Cancer Biology; Cancer Center; Cancer Center Support Grant; Cancer Control; Cancer Hospital; Cancer Immunology Science; Cancer Patient; Caring; Cesium; Clinical; Clinical Sciences; Clinical Trials; Comprehensive Cancer Center; Development; Developmental Therapeutics Program; Education; Epidemiology; Etiology; Evaluation; Flow Cytometry; Fostering; Funding; Goals; Growth; Hospitals; Institutes; Instruction; Leadership; Malignant Neoplasms; Mission; Molecular; Molecular Virology; Morbidity - disease rate; Pain; Pathology; Patient Care; Patients; Population; Population Sciences; Prevention; Process; Publishing; Radiation therapy; Radiobiology; Recruitment Activity; Research; Research Personnel; Resource Sharing; Scientist; Services; Signal Transduction; Strategic Planning; Therapeutic Clinical Trial; Tissues; Training; Translating; Translational Research; United States; Yale Cancer Center; anticancer research; cancer genetics; cancer genomics; cancer prevention; clinical care; end of life; genome analysis; improved; member; mortality; multidisciplinary; next generation; palliative; patient oriented; programs; screening; survivorship; tumor immunology

DESCRIPTION (provided by applicant): The core mission of the Yale Cancer Center is to reduce suffering from cancer by being a global leader in cancer research, care and education. Designated as a Comprehensive Cancer Center in 1974, the past five years have been a period of significant growth and restructuring. Dr. Thomas Lynch became the 6th Director of the YCC in April 2009 and recruited more than 80 new basic, population, translational and clinical scientists. In addition to appointing a new Deputy Director, Dr. Daniel DiMaio, Senior Leadership and cancer Center Administration was completely redesigned. For this submission 6 of 7 Research Programs are under new leadership. During the most recent funding period, the YCCs 260 members published 2751 articles, (21% intra-programmatic and 14% inter-programmatic) and hold $93M in total cancer funding (including $29M from NCI). Accrual to therapeutic clinical trials more than doubled over the past year. Driven by remarkable institutional support, significant expansion during the prior funding period included building the $450M Smilow Cancer Hospital, opening 7 regional Care Centers in Southern CT and acquiring the former Hospital St. Raphael to create the nation's 4th largest hospital. This clinical care expansion was matched by establishing the Yale Cancer Biology Institute at Yale's West Campus. A detailed strategic planning process has begun with a resultant strong emphasis on optimizing our research programs and shared resources and investing in translational research, cancer genetics, and tumor immunology. This 5-year request is to support an organizational framework that promotes and fosters basic and translational cancer research. The 7 Research Programs include: Cancer Genetics and Genomics, Cancer Immunology, Cancer Prevention and Control, Developmental Therapeutics, Molecular Virology, Radiobiology and Radiotherapy and Signal Transduction. Support is requested for 8 Shared Resources including Yale Center for Genome Analysis, Flow Cytometry, Yale Pathology Tissue Services, Cesium Irradiator, Rapid Case Ascertainment, Yale Center for Molecular Discovery, Biostatistics and the Clinical Trials Office. To support center goals and objectives support for Senior Leadership, Planning and Evaluation, Administration, and Developmental Funds is also requested.

描述（由申请人提供）：耶鲁癌症中心的核心使命是通过成为癌症研究、护理和教育的全球领导者来减少癌症的痛苦。1974年被指定为综合癌症中心，过去五年是一个显着的增长和重组时期。托马斯林奇博士于2009年4月成为YCC的第六任主任，并招募了80多名新的基础，人口，翻译和临床科学家。 除了任命一位新的副主任，丹尼尔迪迈奥博士，高级领导和癌症中心管理完全重新设计。对于本次提交的7个研究项目中的6个，将由新的领导人负责。在最近的资助期间，YCC的260名成员发表了2751篇文章（21%的项目内和14%的项目间），并持有9300万美元的癌症资金总额（包括来自NCI的2900万美元）。过去一年，治疗性临床试验的累计费用增加了一倍多。在出色的机构支持的推动下，在上一个资助期内进行了重大扩张，包括建造了4.5亿美元的Smilow癌症医院，在CT南部开设了7个区域护理中心，并收购了前圣拉斐尔医院，以创建全国第四大医院。这种临床护理的扩展是通过在耶鲁大学西校区建立耶鲁癌症生物学研究所来匹配的。详细的战略规划过程已经开始，重点是优化我们的研究计划和共享资源，并投资于转化研究，癌症遗传学和肿瘤免疫学。这个为期5年的请求是为了支持一个促进和促进基础和转化癌症研究的组织框架。7个研究项目包括：癌症遗传学和基因组学，癌症免疫学，癌症预防和控制，发育治疗学，分子病毒学，放射生物学和放射治疗和信号转导。需要支持8个共享资源，包括耶鲁基因组分析中心、流式细胞术、耶鲁病理组织服务、铯辐照、快速病例确定、耶鲁分子发现中心、生物统计和临床试验办公室。为了支持中心的目标和目的，还要求为高级领导、规划和评估、行政和发展基金提供支持。